Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Yaben Chemistry: Planning to raise no more than 1.01B yuan through a private placement for projects including high-end pesticides and pharmaceutical intermediates
(Source: Jinghua Da Butong)
On April 3rd, Yabao Chemical (300261.SZ) announced plans to raise no more than 1.01B yuan through a private placement. After deducting issuance costs, the funds will be used for an annual production of 700 tons of high-end pesticide intermediates, a pilot project for 35 tons of high-end pharmaceutical intermediates, a new project to produce 2,019 tons of raw materials and intermediates (Phase I), a new project to produce 140 tons of pharmaceutical raw materials, a new project to produce 50 tons of Regorafenib, 2 tons of SERD inhibitors, construction of a R&D center, and working capital supplementation.
The basic information of this fundraising investment project is as follows:
Annual production of 700 tons of high-end pesticide intermediates project
This project focuses on capacity building for high-end green pesticide intermediates, centered on the large-scale production of core nitrogen-containing heterocyclic fine chemical intermediates. It emphasizes two high-end pesticide intermediates: amino furan and methyl pyridine amine. Amino furan is a new, efficient, low-toxicity herbicide key intermediate suitable for weed control in crops such as grains, beans, fruits, and vegetables; methyl pyridine amine is a new low-toxicity insecticide core intermediate, widely applicable in rice, wheat, corn, and other field crop pest control. Both are critical raw materials supporting the construction of a green agricultural protection system.
After completion, the project will have a stable capacity of 500 tons of amino furan and 200 tons of methyl pyridine amine annually, further deepening strategic cooperation with key clients, helping the company seize opportunities in the green plant protection industry transformation, strengthening core raw material supply capabilities, and enhancing market competitiveness and industry influence.
The total planned investment for this project is 169.9308 million yuan, with 159 million yuan planned to be raised.
The construction period is planned for 24 months.
The project implementation entity is Gansu Lanwo Technology Co., Ltd., located in Lanzhou, Gansu Province.
Annual production of 35 tons of high-end pharmaceutical intermediates pilot project
This project focuses on pilot transformation of high-end pharmaceutical intermediates. After completion, it will have a pilot-scale production capacity of 5 tons of 5,5-difluoro-1,3,2-dioxathiacyclohexane oxide, 10 tons of bromomethyl methylpyridine, and 20 tons of 4-bromo-1-chloro-2-(4-ethoxy-3-fluorobenzyl)benzene. The products correspond to fluorine-containing fine chemical intermediates, advanced intermediates for new magnetic resonance contrast agents, and intermediates for diabetes treatment drugs. It also helps to streamline the entire chain from R&D to pilot verification to large-scale production, improving service capacity and response efficiency for downstream innovative drug companies, and helping the company grasp the dividends of pharmaceutical industry development.
The total planned investment is 40 million yuan, with 37 million yuan planned to be raised.
The construction period is planned for 12 months.
The project implementation entity is Lanzhou Yabao Pharmaceutical Innovation Technology Co., Ltd., located in Lanzhou, Gansu Province.
New project to produce 2,019 tons of raw materials and intermediates (Phase I)
This project aims to independently build high-end manufacturing capacity that meets international and domestic standards, with a complete quality management system for raw materials and APIs, enhancing the company’s CDMO capabilities. It focuses on industrial upgrading of high-end pharmaceutical intermediates and APIs in cardiovascular and antiepileptic fields, including the layout of nebivolol epoxide intermediates, nebivolol APIs, and levetiracetam APIs, precisely aligning with the rigid demand for clinical drugs downstream and industry trends toward high-quality development and domestic substitution of high-end APIs. After completion, it will have a capacity of 23.4 tons of nebivolol epoxide (including 13.4 tons for internal use), 10 tons of nebivolol, and 50 tons of levetiracetam, ensuring stable supply of core raw materials, improving product supply efficiency and quality, expanding market share, and strengthening industry chain support and overall competitiveness.
The total planned investment is 144 million yuan, with 137 million yuan planned to be raised.
The construction period is planned for 24 months.
The project implementation entity is Yabao (Shaoxing) Pharmaceutical Co., Ltd., located in Shaoxing, Zhejiang Province.
New project to produce 140 tons of pharmaceutical raw materials
This project focuses on the industrialization of innovative high-end pharmaceutical raw materials for diabetes and imaging contrast agents, precisely targeting the track of chronic disease treatment and diagnostic raw materials, aligning with the trend of domestic high-end raw material substitution and clinical supply optimization, deepening the company’s integration into the innovative pharmaceutical industry chain.
After completion, it will have a capacity of 40 tons of 1,2,3,4-tetrahydro-2,2-dimethyl-1,4-benzoxazine-3-carboxylic acid and 100 tons of tetrazolopyridine complex, meeting the growing demand in diabetes and imaging diagnostics, filling the gap in high-end raw material supply; simultaneously, it will improve downstream drug production security and supply stability, consolidating the industry’s independent supporting foundation, and achieving dual benefits of economic efficiency and social healthcare value.
The total planned investment is 286 million yuan, with 281 million yuan planned to be raised.
The construction period is planned for 24 months.
The project implementation entity is Yabao (Shaoxing) Pharmaceutical Co., Ltd., located in Shaoxing, Zhejiang Province.
New project to produce 50 tons of Regorafenib and 2 tons of SERD inhibitors
This project focuses on the industrial upgrading of innovative raw materials for major diseases such as type 2 diabetes and breast cancer, with core products Regorafenib and SERD inhibitors, closely aligned with unmet clinical needs and the trend of domestic innovation drug substitution. It explores the value of drug R&D and large-scale production in niche areas. After completion, it will have a capacity of 50 tons of Regorafenib and 2 tons of SERD raw materials, helping the base shift from a mixed mode of intermediates and APIs to a specialized production base for innovative APIs, strengthening the company’s CDMO service capabilities in high-activity and complex synthesis, and promoting the transformation of the base from traditional intermediate-API mixed production to high-value-added innovative API manufacturing.
The total planned investment is 200 million yuan, with all funds raised through the offering.
The construction period is planned for 12 months.
The project implementation entity is Yabao Chemical Co., Ltd., located in Suzhou, Jiangsu Province.
R&D Center Construction Project
This project aligns with the trend of intelligent and green transformation in the fine chemical and pharmaceutical industries, targeting the pain points of traditional R&D models such as long cycles, high costs, low efficiency, and data barriers. It centers on AI large model technology empowerment and integrated digital systems, promoting full-process quality improvement and iterative upgrades. After implementation, it will establish a central integrated control platform, a fully traceable experimental database, and a GLP-compliant data system, forming a closed-loop management mechanism of “R&D—Data—Verification—Iteration,” filling digitalization gaps, and significantly improving R&D result conversion efficiency. It will provide strong technical support for product line iteration, process optimization, and capacity expansion.
The total planned investment is 31.9225 million yuan, with 31 million yuan planned to be raised.
The construction period is planned for 24 months.
The project implementation entity is Shanghai Puyi Chemical Technology Co., Ltd., located in Pudong New Area, Shanghai.
Working Capital Supplementation
According to the company’s development plan, the company intends to use 160 million yuan of raised funds to supplement working capital, helping to alleviate the company’s funding pressure during development and ensuring sustainable growth.